Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | PRKACG | P22612 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938372 | 0.94 | PIK3CA (0.75) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL11938378 | 0.93 | PIK3CA (0.73) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL11938371 | 0.92 | PIK3CA (0.74) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL11938401 | 0.87 | PIK3CA (0.70) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL28538508 | 0.87 | PIK3CA (0.71) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL11938375 | 0.83 | PIK3CA (0.70) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL11938373 | 0.83 | PIK3CA (0.72) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL15682001 | 0.82 | PIK3CA (0.71) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL11938397 | 0.80 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CDPIK3CGGAK | |
| SCHEMBL11938369 | 0.80 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |